Market capitalization | $1.61b |
Enterprise Value | $2.12b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.15 |
P/S ratio (TTM) P/S ratio | 3.91 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 29.92% |
Revenue (TTM) Revenue | $412.58m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
11 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:
11 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 413 413 |
30%
30%
|
|
Gross Profit | 403 403 |
30%
30%
|
|
EBITDA | -39 -39 |
63%
63%
|
EBIT (Operating Income) EBIT | -41 -41 |
62%
62%
|
Net Profit | -124 -124 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
Head office | United States |
CEO | Jon Stonehouse |
Employees | 536 |
Founded | 1986 |
Website | www.biocryst.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.